dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Miguel-Huguet, Bernat |
dc.contributor.author | Perez-Garcia, Jose Manuel |
dc.contributor.author | Llombart-Cussac, Antonio |
dc.contributor.author | Cortés Castan, Javier |
dc.contributor.author | Pérez López, Jorge |
dc.contributor.author | Sampayo-Cordero, Miguel |
dc.contributor.author | Malfettone, Andrea |
dc.date.accessioned | 2022-02-24T16:39:17Z |
dc.date.available | 2022-02-24T16:39:17Z |
dc.date.issued | 2021-06-22 |
dc.identifier.citation | Sampayo-Cordero M, Miguel-Huguet B, Malfettone A, Pérez-García JM, Llombart-Cussac A, Cortés J, et al. The Impact of Excluding Nonrandomized Studies From Systematic Reviews in Rare Diseases: “The Example of Meta-Analyses Evaluating the Efficacy and Safety of Enzyme Replacement Therapy in Patients With Mucopolysaccharidosis.” Front Mol Biosci. 2021 Jun 22;8:690615. |
dc.identifier.issn | 2296-889X |
dc.identifier.uri | https://hdl.handle.net/11351/7081 |
dc.description | Estudi no aleatoritzat; Malaltia rara; Revisió sistemàtica |
dc.language.iso | eng |
dc.publisher | Frontiers Media |
dc.relation.ispartofseries | Frontiers in Molecular Biosciences;8 |
dc.rights | Attribution 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ |
dc.source | Scientia |
dc.subject | Avaluació de resultats (Assistència sanitària) |
dc.subject | Enzims - Ús terapèutic |
dc.subject | Malalties rares |
dc.subject.mesh | Enzyme Replacement Therapy |
dc.subject.mesh | /methods |
dc.subject.mesh | Rare Diseases |
dc.subject.mesh | Treatment Outcome |
dc.title | The Impact of Excluding Nonrandomized Studies From Systematic Reviews in Rare Diseases: “The Example of Meta-Analyses Evaluating the Efficacy and Safety of Enzyme Replacement Therapy in Patients With Mucopolysaccharidosis” |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.3389/fmolb.2021.690615 |
dc.subject.decs | tratamiento de sustitución enzimática |
dc.subject.decs | /métodos |
dc.subject.decs | enfermedades raras |
dc.subject.decs | resultado del tratamiento |
dc.relation.publishversion | https://doi.org/10.3389/fmolb.2021.690615 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Sampayo-Cordero M, Malfettone A] Medica Scientia Innovation Research (MedSIR), Barcelona, Spain. [Miguel-Huguet B] Colorectal Unit, Department of Surgery, Hospital de Bellvitge, Barcelona, Spain. [Pérez-García JM] Medica Scientia Innovation Research (MedSIR), Barcelona, Spain. IOB Institute of Oncology, Quiron Salud Group, Madrid, Spain. [Llombart-Cussac A] Medica Scientia Innovation Research (MedSIR), Barcelona, Spain. Hospital Arnau de Vilanova, Universidad Católica de Valencia San Vicente Mártir, Valencia, Spain. [Cortés J] Medica Scientia Innovation Research (MedSIR), Barcelona, Spain. IOB Institute of Oncology, Quiron Salud Group, Madrid, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Pérez-López J] Servei de Medicina Interna, Vall d’Hebron Hospital Universitari, Barcelona, Spain |
dc.identifier.pmid | 34239895 |
dc.identifier.wos | 000669662300001 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |